生物制剂在幼年特发性关节炎的应用  

Application of biological agents in JIA

作　　者：周志轩[1] 苏改秀[1] ZHOU Zhi-xuan;SU Gai-xiu(National Center for Children’s Health(Beijing),Department of Rheumatism and Immunology,Children’s Hospital,Capital Institute of Pediatrics,Beijing 100020,China)

机构地区：[1]国家儿童医学中心(北京),首都儿科研究所附属儿童医院风湿免疫科,北京100020

出　　处：《中国实用儿科杂志》2021年第1期19-23,共5页Chinese Journal of Practical Pediatrics

摘　　要：过去20余年幼年特发性关节炎(JIA)的治疗理念不断变革,JIA目标治疗概念的提出亟需临床对生物制剂应用于JIA的策略做出梳理。JIA是异质性疾病,各型别免疫学发病机制不同,带来了不同的治疗靶点。应用于JIA的生物制剂包括:作用于细胞因子的肿瘤坏死因子(TNF)-α抑制剂、白介素-1拮抗剂、白介素-6拮抗剂;作用于T淋巴细胞的阿巴昔普、作用于B淋巴细胞的利妥昔单抗;靶向合成的小分子激酶抑制剂。文章将结合国内外应用现状分别对这些药物在JIA的应用进行介绍。In the past 20 years,the treatment for juvenile idiopathic arthritis(JIA)has been improving constantly.In order to make full use of target therapy in JIA,we need to clarify the clinical application of biological agents.JIA is a heterogeneous disease with different immunological pathogenesis and different target sites.Many biological agents can be used in treating JIA,including TNF-αinhibitors,IL-1 antagonists and IL-6 antagonists which are acting on cytokines,abatacept acting on T lymphocytes,rituximab acting on B lymphocytes,and cellular targets of small-molecule protein kinase inhibitors.In the article,we will introduce the application of these drugs in treating JIA respectively based on the current treatment strategy both in China and abroad.

关 键 词：幼年特发性关节炎 生物制剂 

分 类 号：R72[医药卫生—儿科]